 |
市場調查報告書
商品編碼
1136955
人結核疫苗市場:各給藥途徑，各年齡層，各流通管道，各地區- 規模，佔有率，展望，機會分析，2022年～2030年Human Tuberculosis Vaccine Market, by Route of Administration, by Age Group, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030 |
||||||
價格
簡介目錄
市場動態
結核病預防意識的提高預計將在預測期內推動全球人類結核病疫苗市場的增長。
本調查的主要特徵
- 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球人結核疫苗市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球人結核疫苗市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球人結核疫苗市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球人結核疫苗市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱的說明
第2章 市場展望
- 報告內容
- 市場定義和範圍
- 摘要整理
- 市場概述:各給藥途徑
- 市場概述:各年齡層
- 市場概述:各流通管道
- 市場概述:各地區
- 連貫機遇地圖(COM)
第3章 市場動態，法規，及趨勢的分析
- 市場動態
- 促進因素
- 阻礙因素
- 商機
- 影響分析
- 主要的發展情形
- 產業趨勢
- 法規方案
- 最近產品認證/上市
- PEST分析
- 波特分析
第4章 人結核疫苗的全球市場-冠狀病毒(COVID-19)疫情的影響
- 需求的影響
- 醫療保健的影響
- 流行病學
第5章 人結核疫苗的全球市場:各給藥途徑，2017年～2030年
- 皮內給藥(Intradermal
- 經皮給藥
第6章 人結核疫苗的全球市場:各年齡層，2017年～2030年
- 小兒科
- 成人
第7章 人結核疫苗的全球市場:各流通管道，2017年～2030年
- 公共
- 私人
第8章 人結核疫苗的全球市場:各地區，2017年～2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他的南美地區
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他的歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東地區
- GCC
- 以色列
- 其他的中東地區
- 非洲
- 南非
- 中非
- 北非
第9章 競爭情形
- 熱圖分析
- 市場佔有率分析
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Serum Institute of India Pvt. Ltd.
- Valneva SE
- Archivel Farma
- BIOFABRI(Zendal)
- Japan BCG Laboratory
- GreenSignal Bio Pharma Private Limited(GSBPL)
- AJ Vaccines A/S
- Taj Pharma India Limited
- Biomed Lublin S.A.
第10章 章節
- 調查手法的介紹
- 關於出版社
簡介目錄
Product Code: CMI5209
Mycobacterium tuberculosis is the bacteria that causes tuberculosis. TB germs are most commonly found in the lungs, although they can also be found in the kidney, spine, and brain. Latent tuberculosis infection (LTBI) and tuberculosis illness are two TB-related diseases. The Bacille Calmette-Guerin (BCG) vaccination is used to prevent tuberculosis (TB). In the U.S., this vaccine is not extensively utilized. It is, nevertheless, frequently given to newborns and small children in other countries where tuberculosis is prevalent. The BCG vaccine does not always protect people from contracting tuberculosis. Pediatric tuberculosis is a public health problem of particular importance since it is a marker of recent transmission of tuberculosis.
Market Dynamics
Increasing awareness for prevention of tuberculosis is expected to drive growth of the global human tuberculosis vaccine market during the forecast period. For instance, in March 2022, Johnson & Johnson Philippines Inc., a subsidiary of Johnson & Johnson, and the Philippine Tuberculosis Society Inc. (PTSI), a non-profit, nongovernment organization, rolled out their joint priority project in 2022, a campaign to find the 'missing millions' affected by tuberculosis (TB) among the country's youth and help them improve their lung health with the right treatment
Increasing government initiatives to combat tuberculosis is expected to drive the market growth of global human tuberculosis vaccine market. For instance, in March 2018, the Ministry of Health and Prevention, MOHAP, organized an event in observation of World Tuberculosis Day, under the slogan 'We need leaders to create a world free from tuberculosis'. The event was held to create awareness about the seriousness of tuberculosis and identify its symptoms and ways of transmission.
Key features of the study:
- This report provides an in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global human tuberculosis vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include GlaxoSmithKline Plc, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharma India Limited, and Biomed Lublin S.A.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market
Detailed Segmentation:
- Global Human Tuberculosis Vaccine Market, by Route of Administration :
- Intradermal
- Percutaneous
- Global Human Tuberculosis Vaccine Market, by Age Group :
- Pediatrics
- Adults
- Global Human Tuberculosis Vaccine Market, by Distribution Channel :
- Public
- Private
- Global Human Tuberculosis Vaccine Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- GlaxoSmithKline Plc *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Serum Institute of India Pvt. Ltd.
- Valneva SE
- Archivel Farma
- BIOFABRI (Zendal)
- Japan BCG Laboratory
- GreenSignal Bio Pharma Private Limited (GSBPL)
- AJ Vaccines A/S
- Taj Pharma India Limited
- Biomed Lublin S.A.
- GlaxoSmithKline Plc *
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Industry Trends
- Regulatory Scenario
- Recent Product Approval/Launches
- PEST Analysis
- Porter's Analysis
4. Global Human Tuberculosis Vaccine Market- Impact of Coronavirus (COVID-19) Pandemic
- Impact on Demand
- Impact on Healthcare
- Epidemiology
5. Global Human Tuberculosis Vaccine Market, By Route of Administration, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Intradermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Percutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
6. Global Human Tuberculosis Vaccine Market, By Age Group, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
7. Global Human Tuberculosis Vaccine Market, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Mn)
8. Global Human Tuberculosis Vaccine Market, By Region, 2017 - 2030 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030(%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
- North America
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Age Group, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030 (US$ Mn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valneva SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Archivel Farma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BIOFABRI (Zendal)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Japan BCG Laboratory
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GreenSignal Bio Pharma Private Limited (GSBPL)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AJ Vaccines A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Taj Pharma India Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biomed Lublin S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About Us
